The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants
Issued Date
2026-01-21
Resource Type
ISSN
09598278
eISSN
14735709
Scopus ID
2-s2.0-105035617669
Pubmed ID
41562867
Journal Title
European Journal of Cancer Prevention
Volume
Publish Ahead of Print
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Cancer Prevention Vol.Publish Ahead of Print (2026)
Suggested Citation
Pradutchon S., Pithukpakorn M., Poonyakanok V. The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants. European Journal of Cancer Prevention Vol.Publish Ahead of Print (2026). doi:10.1097/CEJ.0000000000001005 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/116295
Title
The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Germline BRCA1 and BRCA2 pathogenic and likely pathogenic variants (PVs) significantly increase the risk of breast cancer and ovarian cancer, forming the basis for hereditary breast and ovarian cancer syndrome. Current guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with PVs. This study aimed to evaluate the rate of uptake of RRSO among women with breast cancer who carry germline BRCA PVs. This retrospective study collected data from women with breast cancer who were identified to have germline BRCA PVs between 2020 and 2024 at Siriraj Hospital, Bangkok, Thailand. Baseline characteristics, including age, BMI, underlying diseases, menopausal status, recurrent or metastatic breast cancer, BRCA1 and BRCA2 PVs were recorded. The uptake rate and associated factors of RRSO among these women were analyzed. In addition, the time to surgery and pathological outcomes were evaluated in the RRSO group. One hundred and thirty-eight women were included in the final analysis. Among them, 81 (58.7%) underwent RRSO. Ovarian cancer was detected in six (7.4%) women who underwent RRSO. Factors associated with undergoing RRSO including age greater than or equal to 45 years and the absence of distant metastasis. The median interval between genetic testing and RRSO was 8 months. In the surveillance group, the median follow-up time was 39 months, and no cases of cancer were detected. The RRSO uptake rate among breast cancer patients with germline BRCA PVs was 58.7%. Efforts to improve this rate should focus on understanding reasons for refusal and offering alternative prevention strategies.